Arcellx (ACLX) Non-Current Assets (2021 - 2025)
Arcellx's quarterly Non-Current Assets came in at $141.8 million in Q4 2025, up 26.59% year-on-year from $112.0 million in Q4 2024, and down 22.86% quarter-over-quarter from $183.8 million in Q3 2025.
Arcellx has reported Non-Current Assets for 5 years, with the latest figure at $141.8 million in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Assets rose 26.59% year-over-year to $141.8 million; the trailing twelve-month figure through Dec 2025 stood at $574.8 million (down 16.06% YoY), and the FY2025 full-year result was $141.8 million, up 26.59% from the prior year.
- Non-Current Assets for Q4 2025 stood at $141.8 million, down from $183.8 million in the prior quarter.
- The five-year high for Non-Current Assets was $204.1 million in Q2 2024, with the low at $16.0 million in Q4 2021.
- Average Non-Current Assets over 5 years is $105.3 million, with a median of $108.8 million recorded in 2023.
- Year-over-year, Non-Current Assets surged 270.25% in 2024 and tumbled 50.81% in 2025.
- Tracing ACLX's Non-Current Assets over 5 years: stood at $16.0 million in 2021, then jumped by 193.96% to $47.0 million in 2022, then surged by 131.65% to $108.8 million in 2023, then gained by 2.99% to $112.0 million in 2024, then climbed by 26.59% to $141.8 million in 2025.
- The last three Non-Current Assets figures came in at $141.8 million (Q4 2025), $183.8 million (Q3 2025), and $155.2 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 141.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 141.81 Mn |
| Sep 30, 2025 | 183.84 Mn |
| Jun 30, 2025 | 155.19 Mn |
| Mar 31, 2025 | 93.93 Mn |
| Dec 31, 2024 | 112.02 Mn |
| Sep 30, 2024 | 177.61 Mn |
| Jun 30, 2024 | 204.10 Mn |
| Mar 31, 2024 | 190.96 Mn |
| Dec 31, 2023 | 108.77 Mn |
| Sep 30, 2023 | 122.76 Mn |
| Jun 30, 2023 | 65.46 Mn |
| Mar 31, 2023 | 51.58 Mn |
| Dec 31, 2022 | 46.95 Mn |
| Sep 30, 2022 | 47.02 Mn |
| Jun 30, 2022 | 49.58 Mn |
| Mar 31, 2022 | 22.60 Mn |
| Dec 31, 2021 | 15.97 Mn |